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Abstract
Background: Persistent hepatitis B virus (HBV) infection is a risk factor for hepatocellular carcinoma (HCC)
development. This study aimed to clarify whether the high HBV DNA level is associated with HCC development by
comparing HBV DNA levels between HBV infected patients with and without HCC.
Results: There were 78 male and 12 female patients in each group and there was no statistical difference between
these two group patients’ average ages. The HBV DNA level in the HCC patients was 4.73 ± 1.71 Log10 IU/ml while
3.90 ± 2.01 Log10 IU/ml in non-HCC patients (P < 0.01). The HBeAg positive rate was 42.2% (38/90) in the HCC
group while 13.3% (12/90) in the non-HCC group (P < 0.001). Compared with patients with HBV DNA level of < 3
Log10 IU/ml, the patients with level of 3 to < 4, 4 to < 5, 5 to < 6, or ≥ 6 Log10 IU/ml had the odds ratio for HCC
of 1.380 (95% CI, 0.544-3.499), 3.671 (95% CI, 1.363-9.886), 5.303 (95% CI, 1.847-15.277) or 3.030 (95% CI, 1.143-8.036),
respectively.
Conclusions: HBV-related HCC patients had higher HBV DNA level than non-HCC counterparts. Our findings imply
that active HBV replication is associated with the HCC development.
Background
Chronic hepatitis B virus (HBV) infection is a serious
public health problem worldwide since more than 350
million people are chronic carriers [1-4]. Persistent HBV
infection is a risk factor for the development of hepato-
cellular carcinoma (HCC). The viral factors, such as
viral genotype and mutants, have been shown to be
associated with the pathogenesis of HCC [5-7]. Recent
studies show that HBV load may also be associated with
the HCC development [8-15] because the HBV DNA
level in HCC patients was higher than that in non-HCC
patients [13-15]. However, other studies showed that the
v i r a ll o a di nH B V - a s s o c i a t e dH C Cp a t i e n t sw a sn o t
higher than that in the patients without HCC [16,17].
HBV infection is still highly endemic in China
although the prevalence of hepatitis B surface antigen
(HBsAg) has been reduced from 10% to 7.18% after the
hepatitis B vaccine has been widely used in infants
[18,19]. The age-standardized incidence of HCC in
China is 58 per 100 000 persons for men and 22 per
100 000 persons for women, which is high in the world
[ 2 0 ] .H o w e v e r ,t h ec o m p a r i s o no fH B VD N Al e v e l
between HCC and non-HCC patients in China has been
less studied [15]. In view of high HBV endemicity and
HCC incidence in China, we performed this study to
compare serum HBV DNA level between chronic hepa-
titis B (CHB) patients with HCC and the patients with
HBV infection alone to clarify whether the high HBV
level is a risk for HCC development.
Results
Patients’ characteristics
In view of the fact that antiviral treatment will influence
the HBV DNA level, we excluded the patients who
received any antiviral treatment before. After these two
group patients were matched for age (fewer than 2 years
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provided the original work is properly cited.difference) and gender respectively, 90 patients were
included in each group. Their average age, serum bio-
chemical values and number of HBeAg positive patients
are expressed in Table 1. Our findings showed the
HBeAg positive rate was 42.2% (38/90) in the HCC
group while 13.3% (12/90) in the non-HCC group (P <
0.001). As shown in Table 2, we found the percentages
of patients with abnormal serum alanine aminotransfer-
ase (ALT), aspartate aminotransferase (AST), total bilir-
ubin or direct bilirubin of HCC group were higher than
those of non-HCC group. This indicates that higher per-
centage HCC patients are associated with worse liver
function.
Comparison of HCC and non-HCC patients’ HBV DNA
level
As shown in Table 3, we compared the viral load
between HCC patients and non-HCC patients. The
HBV DNA level was higher in HCC group than that in
non-HCC group (4.73 ± 1.71 vs. 3.90 ± 2.01 log10 IU/
ml, P < 0.01). We further analyzed the viral load of
HCC or non-HCC patients stratified by age. The HBV
DNA level in HCC group was significantly higher than
that of the non-HCC patients in the age range of 50-59
years. This was the same with the age range of below 40
years.
The odds ratios (ORs) for the association between
HCC and various serum HBV DNA level are shown in
Table 4. Compared with patients with HBV load of < 3
log10 IU/ml, patients with 3 to < 4, 4 to < 5, 5 to < 6, or
≥ 6l o g 10 IU/ml HBV DNA level had the ORs of 1.380
(95% CI, 0.544-3.499), 3.671 (95% CI, 1.363-9.886),
5.303 (95% CI, 1.847-15.277) or 3.030 (95% CI, 1.143-
8.036), respectively. These results indicate that patients
with serum HBV DNA level of above 10
4 IU/ml have a
higher risk to develop HCC.
Discussion
We quantitatively measured serum HBV load in 90 HBV
infected patients with HCC and in 90 age- and gender-
matched patients with HBV infection alone and found
that HCC patients had higher serum HBV DNA level
than patients without HCC, especially in the age range
of 50-59 years or below 40 years. The data in the pre-
sent study indicate that the patients with higher HBV
level have more risk to develop HCC.
There were a few retrospective studies in which the
authors compared HCC and non-HCC patients’ HBV
DNA level to clarify the role of HBV load in HCC
development. Some authors stated the level in HCC
patients was higher than that in non-HCC patients
[14,15] and > 10
4 [21] or > 10
5 [13] copies/ml HBV
Table 1 Characteristics of HCC and non-HCC patients
Characteristics HCC (n = 90) non-HCC (n =
90)
P
value
Male/Female 78/12 78/12
Age 52.53 ± 10.27 52.53 ± 10.23 1.000
HBeAg positive 38 12 < 0.001
Total Protein (g/L) 68.2 ± 6.8 65.5 ± 8.1 0.017
Albumin (g/L) 38.5 ± 5.0 38.9 ± 6.4 0.657
Globulin (g/L) 29.7 ± 6.5 26.6 ± 5.6 0.001
ALT (IU/L) 47.50 (7.9-926.7) 25.05 (7.1-1660.5) < 0.001
AST (IU/L) 48.15 (18.7-
910.9)
26.35 (10.4-1071.1) < 0.001
Total Bilirubin (μmol/L) 19.60 (3.6-503.9) 16.8 (6.7-492.7) 0.021
Direct Bilirubin (μmol/
L)
7.30 (1.7-304.9) 5.15 (1.5-353.1) < 0.001
Table 2 The percentage of patients with abnormal serum
biochemical parameters
Parameters HCC (n = 90) non-HCC (n = 90) P value
ALT 52 (57.8%) 21 (23.3%) < 0.001
AST 53 (58.9%) 27 (30.0%) < 0.001
Total Bilirubin 42 (46.2%) 29 (32.2%) 0.047
Direct Bilirubin 48 (53.3%) 24 (26.7%) < 0.001
Total Protein 16 (17.8%) 21 (23.3%) 0.356
Albumin 23 (25.6%) 20 (22.2%) 0.600
Globulin 18 (20.0%) 14 (15.6%) 0.436
Table 3 Comparison of the HCC and non-HCC patients’
number and viral load stratified by ages
Age
range
(years)
Patients number
(%)
viral load
(Log10 IU/ml, mean ± SD)
HCC non-HCC P
value
HCC non-HCC P
value
All 90
(100)
90 (100) 1.000 4.73 ± 1.71 3.90 ± 2.01 0.003
≥ 60 25
(27.8)
22 (24.4) 0.611 4.48 ± 1.80 3.56 ± 1.35 0.056
50-59 29
(32.2)
32 (35.6) 0.637 5.20 ± 1.52 3.98 ± 2.21 0.015
40-49 27
(30.0)
27 (30.0) 1.000 4.20 ± 1.85 4.20 ± 2.09 0.996
<4 0 9
(10.0)
9 (10.0) 1.000 5.51 ± 0.94 3.61 ± 2.46 0.046
Table 4 Odds ratios for the association between HCC and
various HBV load
HBV load
(IU/ml)
HCC (n) non-HCC (n) OR (95% CI) P value
≥ 10
6 20 15 3.030 (1.143-8.036) 0.045
10
5 -<1 0
6 21 9 5.303 (1.847-15.277) 0.003
10
4 -<1 0
5 21 13 3.671 (1.363-9.886) 0.018
10
3 -<1 0
4 17 28 1.380 (0.544-3.499) 0.659
<1 0
3 11 25 1.000 (reference)
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Page 2 of 5DNA level was supposed to be an independent risk fac-
tor of HCC development. As an indicator of active repli-
cation of HBV, the higher HBeAg positive rate is usually
associated with an increased risk of HCC [22]. Our find-
ings were similar to these previously reported results.
However, in Tsai et al’s paper, there existed no signifi-
cant difference in HCC and non-HCC patients’ HBV
DNA level [16]. Another study performed in India
showed that the HBV DNA load in HCC patients was
lower than that of HBV-related chronic liver disease
patients [17]. However, in these two studies, the HCC
group patients were both obviously older than the non-
HCC group patients (53.7 ± 12.7 vs. 32.1 ± 10.0 years
[16], 53.6 ± 13.2 vs. 44.2 ± 14.7 years [17]). The evolu-
tion and the viral load of HBV infection may be influ-
enced by age at acquisition. In the present study,
although it is difficult to determine duration of the
infection for each patient, we considered that most
patients in our study had been infected with HBV in
their infantile or childhood periods as the majority of
chronic HBV infection in China is due to the perinatal
infections [23]. Thus, the comparable patients’ ages in
the HCC and non-HCC groups may represent the simi-
lar infection durations in the two groups. Since HCC is
al o n g - t e r mo u t c o m eo fc h r o n i cH B Vi n f e c t i o na n d
HBV DNA level is usually higher in younger CHB
patients than in older ones [16], the matching of the
patients’ age is essential in the comparison of HBV
DNA level in patients with or without HCC.
Large number chronic HBsAg carriers in Taiwan were
followed up for a long period and the prospective data
showed an increased risk for cirrhosis and for HCC with
increasing level of HBV DNA [24,25]. Several studies
have suggested an increased risk of HCC with high
HBV DNA level (> 10
6 copies/ml [9], 10
4-10
7 copies/ml
[26] or > 10
5 copies/ml [27]). In our study, the data
demonstrated that the patients with higher than 10
4 IU/
ml HBV DNA level had more risk to be diagnosed as
HCC, which was similar to the previous prospective
reports [25-29]. The commonly used quantitative units
of HBV DNA level in papers are IU/ml and copies/ml.
In the current WHO HBV standard and consensus, one
IU is approximately equivalent to five genome equiva-
lents (copies) [30]. The viral load of 10
4 IU/ml identified
in this study is approximately equal to 5 × 10
4 copies/
ml.
Conclusions
In summary, our findings demonstrated that higher
serum HBV load in HCC patients than non-HCC coun-
terparts, especially in the age range of both 50-60 years
and below 40 years. Our results suggest that patients
with higher than 10
4 IU/ml HBV DNA level are asso-
ciated with more risk to develop HCC.
Methods
Patients and study design
A total of 388 CHB patients were admitted to Nanjing
Drum Tower Hospital between October 2009 and June
2010. All patients were positive for HBsAg for at least 6
months. One group included 120 CHB patients who
were diagnosed with HCC for the first time. The diag-
n o s i so fH C Cw a sm a d eb yp a t h o l o g i c a lf i n d i n g so ra
combination of elevated a-fetoprotein (> 400 ng/ml)
and typical appearance on at least two radiological ima-
ging techniques, including ultrasonography, computer-
ized tomography, magnetic resonance imaging, or
hepatic angiography with lipiodol. The other group was
268 CHB patients without HCC. The patients with
hepatitis C virus (HCV) or HIV co-infection, primary
biliary cirrhosis, autoimmune hepatitis, significant alco-
hol intake or Wilson’s disease were excluded. After we
excluded the patients who received any antiviral treat-
ment before, these two group patients were matched for
age (fewer than 2 years difference) and gender respec-
tively. As a result, there were 90 patients in each group.
All study participants provided informed written con-
sent. All the experiments were approved by the Ethics
Committee of Nanjing Drum Tower Hospital, Nanjing
University Medical School, in accordance with guide-
lines of the Nation Health and Medical Research Coun-
cil of China.
A blood sample was collected from each subject and
the serum was separated by centrifugation at room tem-
perature. The serum was stored in a sterile tube at -20°
C until use. For HCC patients, serum samples were col-
lected before surgical resection or interventional therapy
was performed.
Viral markers assays
HBsAg and hepatitis B e antigen (HBeAg) were tested
by commercial enzyme-linked immunosorbent assays
(ELISA) (Huakang Biotechnology, Shenzhen, China).
Commercial ELISA kit for anti-HCV was obtained from
Huakang (Huakang Biotechnology, Shenzhen, China)
and anti-HIV ELISA kit was from Lizhu (Lizhu Biotech-
nology, Zhuhai, China).
Quantitative assay of HBV DNA
Serum HBV DNA was quantified with a commercial
fluorescent real-time PCR assay (DaAn Gene, Guangz-
hou, China) [31]. Serum DNA was extracted from 100
μl serum by boiling in DNA extract buffer (NaOH, Tris-
HCl, TritonX-100, NP40, chelex-100, EDTA) and was
dissolved in 20 μl DNA solution buffer. Afterwards, 2 μl
D N As o l u t i o nw a ss u b j e c t e dt oP C R .T h eP C Rp r o g r a m
c o n s i s t e do f9 3 ° Cf o r2m i n ,1 0c y c l e so f9 3 ° Cf o r4 5
seconds and 55°C for 60 seconds, 30 cycles of 93°C for
30 seconds and 55°C for 45 seconds. The fluorescence
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for 45 seconds by 7500 real time PCR system (Applied
Biosystems, Singapore). The lower detection limit of this
assay was 10
3 IU/ml with a linear range of up to 10
7 IU/
ml. The known amounts of 10
3,1 0
4,1 0
5,1 0
6,1 0
7 IU/ml
HBV DNA were used as a control. Strict precautions
were taken to avoid potential contamination.
Statistical analysis
Serum HBV DNA level was log10-transformed for analy-
sis. Normal distribution data were expressed as mean ±
standard deviation and non-normal distribution data
were given as median with range. All the HBV DNA
levels below the detection limit (3 log10 IU/ml) were
defined as non-measured values and they were arbitra-
rily estimated as 1.5 log10 IU/ml in analysis for the rea-
son of estimated continuous distribution of the HBV
DNA levels. The differences in liver function and serum
DNA level between HCC and non-HCC patients were
evaluated by Pearson’s Chi-square test, Student’s t test
and Mann-Whitney u test where appropriate. All esti-
mates were accompanied by a 95% confidence interval
(CI) where appropriate and two-sided P values of fewer
than 0.05 were considered statistically significant.
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